Stereotactic Body Radiotherapy of Lymph Node Oligometastases

Česká verzia

Authors: Petr Burkoň ^1,2; Sabina Oberreiterová ¹; Tomáš Kazda ^1,2; Marek Slávik ^1,2; Lukáš Bobek ¹; Libor Komínek ¹; Tomáš Procházka ^1,2; Miroslav Vrzal ^1,2; Pavel Šlampa ^1,2
Authors place of work: Klinika radiační onkologie, Masarykův onkologický ústav, Brno 2 Klinika radiační onkologie, LF MU, Brno ¹
Published in the journal: Klin Onkol 2020; 33(2): 114-122
Category: Original Articles
doi: https://doi.org/10.14735/amko2020114

Summary

Background: The aim of this retrospective study is to evaluate the efficacy and toxicity of extracranial stereotactic radiotherapy for the treatment of oligometastatic lymph node involvement in the mediastinum, retroperitoneum, and pelvis in a consecutive group of patients from real clinical practice.

Material and methods: Of a total of 50 patients treated between 2011 and 2017, 29 were men and 21 were women, and the mean age was 62 years (median 66 years, range 25–81 years). Patients were most often irradiated in five fractions; the dose was selected according to dose-volume histograms of organs-at-risk in proximity to the planning target volume. The primary objectives were local control (LC), progression-free survival (PFS), time to multiple dissemination not allowing the use of local treatment methods (freedom from widepread dissemination – FFWD), and overall survival (OS). Acute and delayed toxicity were evaluated as well.

Results: The median dose equivalent at α/β = 10 (BED10) was 54 Gy (range 48–80 Gy). The median follow-up period was 40.4 months. LC after irradiation was 90% in 1 year and 75% in 3 years. Median time to local progression was not achieved. Patients irradiated with a high dose had significantly better LC than patients irradiated with a low dose; the cut-off was the median of the applied dose (ie BED10 = 54 Gy). Pathological node localization had no significant effect on LC. The median PFS was 8.2 months (95% CI 7.4–11.6 months). PFS in 1 year was 38.5% and 17% in 3 years. The median OS was 37.3 months (95% CI 23.2–51.4 months). One-year OS was 83% and 3-year OS was 51%. The median FFWD was 13.6 months (range 8.7–18.5 months). The one-year FFWD was 55% and the 3-year FFWD was 24%. None of these parameters (PFS, OS, FFWD) was dose or localization dependent. No grade III or IV toxicity was reported.

Conclusion: Our study shows that targeted stereotactic radiotherapy is a very effective low toxic treatment for oligometastatic lymph node involvement. It can delay cytotoxic chemotherapy and thus improve/maintain the quality of life of patients. Approximately one fifth of patients treated with extracranial stereotactic radiotherapy for oligometastatic lymph node involvement survived without signs of disease for prolonged periods. Future studies should aim at identifying patients who would benefit most from this treatment, adjusting the timing of extracranial stereotactic radiotherapy depending on the treatment strategy, and optimizing the dose prescription.

This work was supported by grant of the Ministry of Health of the Czech Republic AZV 19-00354 and by grant of the Ministry of Health of the Czech Republic – Conceptual development of a research organization (MMCI 00209805).

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.

Keywords:

radiotherapy – metastases – stereotactic body radiotherapy – lymph node metastases – oligometastases – local therapy

Zdroje

1. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995; 13 (1): 8–10. doi: 10.1200/JCO.1995.13.1.8.

2. Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol 2011; 8 (6): 378–382. doi: 10.1038/nrclinonc.2011.44.

3. Niibe Y, Hayakawa K. Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn J Clin Oncol 2010; 40 (2): 107–111. doi: 10.1093/jjco/hyp167.

4. Bignardi M, Navarria P, Mancosu P et al. Clinical outcome of hypofractionated stereotactic radiotherapy for abdominal lymph node metastases. Int J Radiat Oncol Biol Phys 2011; 81 (3): 831–838. doi: 10.1016/j.ijrobp.2010.05. 032.

5. Burkoň P, Slávik M, Kazda T et al. Extrakraniální stereotaktická radioterapie – přehled současných indikací. Klin Onkol 2019; 32 (1): 10–24. doi: 10.14735/amko201910.

6. Ettinger DS, Wood DE, Aisner DL et al. NCCN Guidelines insights: non-small cell lung cancer, version 5.2018. J Natl Compr Canc Netw 2018; 16 (7): 807–821. doi: 10.6004/ jnccn.2018.0062.

7. Postmus PE, Kerr KM, Oudkerk M et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28 (Suppl 4): 1–21. doi: 10.1093/annonc/mdx222.

8. Videtic GM, Donington J, Giuliani M et al. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO EvidenceBased Guideline. Pract Radiat Oncol 2017; 7 (5): 295–301. doi: 10.1016/j.prro.2017.04.014.

9. Tree AC, Khoo VS, Eeles RA et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol 2013; 14 (1): 28–37. doi: 10.1016/S1470-2045 (12) 70510-7.

10. Corbin KS, Hellman S, Weichselbaum RR. Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. J Clin Oncol 2013; 31 (11): 1384–1390. doi: 10.1200/JCO.2012.45.9651.

11. Palma DA, Olson RA, Harrow S et al. Stereotactic ablative radiation therapy for the comprehensive treatment of oligometastatic tumors (SABR-COMET): results of a randomized trial. Int J Radiat Oncol Biol Phys 2018; 102 (3): S3–S4. doi: 10.1016/j.ijrobp.2018.06.105.

12. Burkoň P, Šlampa P, Kazda T et al. Stereotactic body radiation therapy for colorectal cancer liver metastases; early results. Klin Onkol 2012; 25 (Suppl 2): 2S93–2S97. doi: 10.14735/amko20122S93.

13. Nagata Y, Takayama K, Matsuo Y et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2005; 63 (5): 1427–1431. doi: 10.1016/j.ijrobp.2005.05.034.

14. Heinzerling JH, Anderson JF, Papiez L et al. Four-dimensional computed tomography scan analysis of tumor and organ motion at varying levels of abdominal compression during stereotactic treatment of lung and liver. Int J Radiat Oncol Biol Phys 2008; 70 (5): 1571– 1578. doi: 10.1016/j.ijrobp.2007.12.023.

15. Nagata Y, Wulf J, Lax I, et al. Stereotactic radiotherapy of primary lung cancer and other targets: results of consultant meeting of the International Atomic Energy Agency. Int J Radiat Oncol Biol Phys 2011; 79: 660–669. doi: 10.1016/j.ijrobp.2010.10.004.

16. Lagerwaard FJ, Haasbeek CJ, Smit EF et al. Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008; 70 (3): 685–692. doi: 10.1016/j.ijrobp.2007.10.053.

17. Benedict SH, Yenice KM, Followill D et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys 2010; 37 (8): 4078–4101. doi: 10.1118/1.3438081.

18. Ong CL, Verbakel WFAR, Cuijpers JP, et al. Stereotactic radiotherapy for peripheral lung tumors: a comparison of volumetric modulated arc therapy with 3 other delivery techniques. Radiother Oncol 2010; 97 (3): 437–442. doi: 10.1016/j.radonc.2010.09.027.

19. Purdie TG, Bissonnette JP, Franks K, et al. Cone-beam computed tomography for on-line image guidance of lung stereotactic radiotherapy: localization, verifcation, and intrafraction tumor position. Int J Radiat Oncol Biol Phys 2007; 68 (1): 243–252. doi: 10.1016/ j.ijrobp.2006.12.022.

20. van Gestel YR, de Hingh IH, van Herk-Sukel MP et al. Patterns of metachronous metastases after curative treatment of colorectal cancer. Cancer Epidemiol 2014; 38 (4): 448–454. doi: 10.1016/j.canep.2014.04.004.

21. Todo Y, Kato H, Minobe S et al. Initial failure site according to primary treatment with or without para-aortic lymphadenectomy in endometrial cancer. Gynecol Oncol 2011; 121 (2): 314–318. doi: 10.1016/j.ygyno.2011.01.019.

22. Shibata D, Paty PB, Guillem JG, et al. Surgical management of isolated retroperitoneal recurrences of colorectal carcinoma. Dis Colon Rectum 2002; 45 (6): 795–801. doi: 10.1007/s10350-004-6300-3.

23. Jereczek-Fossa BA, Ronchi S, Orecchia R. Is stereotactic body radiotherapy (SBRT) in lymph node oligometastatic patients feasible and eﬀective? Rep Pract Oncol Radiother 2015; 20 (6): 472–483. doi: 10.1016/j.rpor.2014.10.004.

24. Jereczek-Fossa BA, Ronchi S, Piperno G et al. Linac-based stereotactic body radiotherapy for oligometastatic patients with single abdominal lymph node recurrent cancer. Am J Clin Oncol 2014; 37 (3): 227–233. doi: 10.1097/COC.0b013e3182610878.

25. Yeung R, Hamm J, Liu M et al. Institutional analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lymph node metastases. Radiat Oncol 2017; 12 (1): 105. doi: 10.1186/s13014-017-0820-1.

26. Loi M, Frelinghuysen M, Klass ND et al. Locoregional control and survival after lymph node SBRT in oligometastatic disease. Clin Exp Metastasis 2018; 35 (7): 625–633. doi: 10.1007/s10585-018-9922-x.

27. Burkon P, Kazda T, Pospisil P et al. Ablative dose stereotactic body radiation therapy for oligometastatic disease: a prospective single institution study. Neoplasma 2019; 66 (2): 315–325. doi: 10.4149/neo_2018_180731N558.

28. Onishi H, Shirato H, Nagata Y et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys 2011; 81 (5): 1352–1358. doi: 10.1016/j.ijrobp.2009.07.1751.

29. Winkel D, Bol GH, Werensteijn-Honingh AM et al. Evaluation of plan adaptation strategies for stereotactic radiotherapy of lymph node oligometastases using online magnetic resonance image guidance. Phys Imaging Radiat Oncol 2019; 9: 58–64. doi: 10.1016/j.phro.2019.02.003.

30. Jereczek-Fossa BA, Fanetti G, Fodor C et al. Salvage stereotactitc body radiotherapy for isolated lymph node recurrent prostate cancer: single institution series of 94 consecutive patients and 124 lymph nodes. Clin Genitourin Cancer 2017; 15 (4): 623–632. doi: 10.1016/ j.clgc.2017.01.004.

31.Wang Z, Wang J, Zhuang H et al. Stereotactic body radiation therapy induces fast tumor control and symptom relief in patients with iliac lymph node metastasis. Sci Rep 2016; 29 (6): 37987. doi: 10.1038/srep 37987.

32. Ost P, Jereczek-Fossa BA, Van As N et al. Pattern of progression after stereotactic body radiotherapy for oligometastatic prostate cancer nodal recurrences. Clin Oncol (R Coll Radiol) 2016; 28 (9): 115–120. doi: 10.1016/ j.clon.2016.04.040.

33. Bignardi M, Navarria P, Mancosu P et al. Clinical outcome of hypofractionated stereotactic radiotherapy for abdominal lymph nodemetastases. Int J Radiat Oncol Biol Phys 2011; 81 (3): 831–838. doi: 10.1016/ j.ijrobp.2010.05.032.

34. Choi CW, Cho CK, Yoo SY et al. Image-guided stereotactic body radiation therapy in patients with isolated para-aortic lymph nodemetastases from uterine cervical and corpus cancer. Int J Radiat Oncol Biol Phys 2009; 74 (1): 147–153. doi: 10.1016/j.ijrobp.2008.07.020.